Physician profile
Mallory A Booth
NPI 1073960118
$5,683.63
in general payments reported to CMS, 2019-2025
60 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $682 · 2022: $2,683 · 2023: $2,235 · 2024: $83.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.57 |
| Education | $252.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.33 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $351.59 | 2021-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $349.44 | 2021-2023 | |
| Seagen INC. | $341.69 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Incyte Corporation | $315.29 | 2022-2023 | Jakafi |
| Janssen Biotech, INC. | $272.03 | 2022-2023 | Darzalex, Imbruvica |
| Sanofi-Aventis U.S. LLC | $197.00 | 2022-2023 | |
| Celgene Corporation | $190.68 | 2022-2023 | Opdualag, Reblozyl |
| Daiichi Sankyo INC. | $164.92 | 2022-2023 | Injectafer, Enhertu |
| Abbott Laboratories | $161.55 | 2021-2022 | |
| Exelixis INC. | $145.09 | 2022 | |
| Amgen INC. | $143.65 | 2021-2023 | Kyprolis, Nplate, Vectibix |
| Glaxosmithkline, LLC. | $136.46 | 2022-2023 | Jemperli, Zejula, Shingrix |
| Eisai INC. | $136.37 | 2021-2023 | |
| Genentech USA, INC. | $125.75 | 2023-2024 | Polivy, Lunsumio, Gazyva |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.